Institutional members access full text with Ovid®

Megavolume Autologous Fat Transfer: Part I. Theory and Principles

Khouri, Roger K. M.D.; Rigotti, Gino M.D.; Cardoso, Eufemiano M.D.; Khouri, Roger K. Jr. B.S.; Biggs, Thomas M. M.D.

Plastic & Reconstructive Surgery: March 2014 - Volume 133 - Issue 3 - p 550–557
doi: 10.1097/01.prs.0000438044.06387.2a
Cosmetic: Special Topics
Discussion
Press Release

Summary: This article describes the theory and principles behind the authors’ success in megavolume (250-ml range) autologous fat transfer to the breasts. When large volumes are grafted into a tight space, the interstitial fluid pressure increases to impair capillary blood flow and the crowded graft droplets coalesce into lakes, with poor graft-to-recipient interface. These factors have historically restricted the volume of fat that can be grafted into small recipient breasts. The decreased interface increases the distance oxygen must diffuse to reach the grafted adipocytes, causing central necrosis to occur before neovascularization. The increased interstitial fluid pressure reduces capillary radius, reducing oxygen delivery to grafted adipose tissue. The Brava external expansion device harnesses the regenerative capabilities of mechanical forces to preoperatively increase the volume and vascularity of the recipient site, allowing megavolumes of fat to be grafted diffusely without significantly decreasing graft-to-recipient interface or increasing interstitial fluid pressure. The application of these principles has allowed the authors to successfully graft megavolumes of fat into the breasts of over 1000 patients with substantial long-term retention.

Miami, Fla.; Ann Arbor, Mich.; Houston, Texas; and Verona, Italy

From the Miami Breast Center; Herbert Wertheim College of Medicine at Florida International University; the University of Michigan Medical School; Baylor College of Medicine; and the University of Verona.

Received for publication April 27, 2013; accepted September 11, 2013.

Disclosure: Roger K. Khouri, M.D., has an equity interest in the company, Brava, LLC, the manufacturer of the Brava device. He also has an equity interest in Lipocosm, the manufacturer and distributor of the Lipografter, consisting of the K-VAC Syringe and the AT-Valve. None of the other authors has any conflicts of interest to disclose.

Roger Karl Khouri, Jr., B.S., 1113 Freesia Court, Ann Arbor, Mich. 48105, rogerkarlkhouri@gmail.com

©2014American Society of Plastic Surgeons